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We have completely purified, in parallel, a low molecular weight, non-peptidic, non-lipidic, Na+,K+-ATPase inhibitory factor from bovine hypo- 
thalamic and pituitary tissues. In the final purification step we obtain, from both tissues, a single, homogeneous peak, with a maximal absorbance 
at 247 nm. This factor, at physiological concentrations of potassium (5-25 mM), inhibits in a dose-response manner Na+,K+-ATPase and displaces 
ouabain from its receptor at the enzyme structure. The factor isolated from both tissues is identical, being the specific activity per weight of tissue 
higher in hypophysis. No factor was found in cerebral cortex, used as tissue control. 
Na+,K+-ATPase; Sodium pump; Ouabain 
1. INTRODUCTION 
The existence of a circulating inhibitor of the 
ouabain-sensitive Na+,K+-ATPase has been implicated 
in several physiological roles, such as renal sodium ex- 
cretion or the genesis of certain forms of hypertension 
[l]. There has been a great deal of effort by several 
groups to identify and characterize aplasma, urinary or 
tissue inhibitor of Na+,K+-ATPase with controversy 
about its chemical structure and its mechanism of ac- 
tion [2]. One reason for this disagreement could be due 
to the use of partially purified preparations that could 
give conflicting results depending on the grade of 
purification achieved. Because the midbrain has been 
imphcated in the control of circulating 
Na+,K+-ATPase inhibitors, the hypothalamus was in- 
itially selected as a source for study. We have reported 
the presence, in crude tissue extracts of bovine 
hypothalamus [3] and hypophysis [4] of a factor that 
reversibly blocks the active transepithelial sodium 
transport across anuran membranes and that inhibits 
Na+,K+-ATPase from mammalian kidney, as well as 
the binding of labelled ouabain to its cellular receptor 
in frog urinary bladder. We have pursued the purifica- 
tion efforts, using a multiple bioassay strategy, with the 
final goal of obtaining a completely pure substance in 
order to determine its chemical structure. In the current 
communication, we describe the final purification of 
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such factor from bovine hypothalamus and 
hypophysis. The identity between the factor obtained 
from both tissues is described. The effect of this pure 
hypothalamic hypophysary inhibitory factor (HHIF) 
on Na+,K+-ATPase and on displacement of [3H]oua- 
bain from its receptor in the enzyme is also reported. 
Data are given about some of its physicochemical 
characteristics. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
[y-“P]ATP (3000 Ci/mmol), [‘Hlouabain (20.6 Ci/mmol) and 
[“sI]digoxin (833 Ci/mmol) were purchased from the Radiochemical 
Center (Amersham, England), NADH from Boehringer Mannheim, 
the enzymes pyruvate kinase and lactate dehydrogenase from Merck 
(Darmstadt). All the other chemicals were purchased from Sigma. 
Organic solvents were of high-performance liquid chromatography 
(HPLC) grade (Merck). Sephadex LH-20 was purchased from Phar- 
macia and all the HPLC columns from Waters. Deionized distilled 
water was used for all solutions. 
2.2. Purification 
Tissue extraction: 1 kg of frozen tissue (bovine hypothalamus, 
hypophysis, cerebral cortex) was extracted according to previously 
described methods [4,5]. Chromatogruphic procedures: the final ex- 
tracts were dissolved in methanol and applied to a Sephadex LH-20 
column, 3.5 x 85 cm equilibrated and eluted with 100% methanol. 
Further purification was achieved by 4 steps of HPLC runs; first on 
a semipreparative Cis PBondapak column (7.8 x 300 mm) of 10 pm 
of particle size, by a step gradient (O-40%, 80 min), (40-80%, 
105 min), (80-lOO%, 110 min) of water/acetonitrile and 0.10/o TFA 
at a flow rate of 2 ml/mitt; second on an analytical Cis Novapak col- 
umn (3.9 x 150 mm) of 4 pm of particle size by an increasing linear 
gradient (O-50%) of water/acetonitrile and 0.1 Vo TFA over 260 min 
at a flow rate of 0.5 ml/mitt; third in a free fatty acid column (FFA) 
(3.9 x 300 mm) of 10 pm of particle size by an increasing linear gra- 
dient (20-80%) of acetonitrile/water with 0.1% TFA over 180 min 
at a flow rate of 0.5 ml/min; fourth on an FFA (3.9 x 300 mm) col- 
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umn of 10 pm of particle size by a step gradient (20~40%, 60 min), 
(40-60%, 120 min), (60~80%, 60 min) of water/acetonitrile with 
0.1% TFA at a flow rate of 0.5 mb’min. The HPLCs were developed 
using a Waters 600E system controller with an IBM computer and a 
Waters 990 photodiode array detector. 
2.3. B&assays 
The chromatographic fractions were freeze-dried and reconstituted 
in water. These fractions were assayed as follows. Na’,K+-ATPase 
activity: the enzyme was purified from porcine kidney outer medulla 
by the procedure of Jorgensen [6]. The inhibitory activity was deter- 
mined by a coupled assay [5,7] and a [y-32P]ATP assay [8]. One unit 
(U) of inhibitory activity was defined as the amount of HHIF re- 
quired to inhibit 8 cg of purified Na+,K+-ATPase by 50% in the 
coupled assay with a concentration of 25 mM KCl. eNjOuabain bin- 
ding displacement: we used the method described by Brooker and 
Jelliffe [P]. Radioimmunoassay: a digoxin kit purchased from Im- 
munochem (USA) was used. Toad bladder assay: in the initial 
puri~~tion steps, the inhibitory activity of the fractions was con- 
firmed by the toad bladder assay as previously described [3]. 
2.4. Characterization 
Physical-chemical treatment: for the acid treatment he conditions 
for amino acid analysis of peptides were employed. 220 U doses of 
HHIF were incubated with 5.7 M HCI and 0.005% mercaptoethanol 
at 115°C for 21 h under vacuum. The remaining HCl was removed 
by lyophilization and the sample was assayed for inhibition of 
Na+,K+-ATPase. Alkaline treatment: 2 U of HHIF were incubated 
with 0.2 NaOH at 27°C for 2 h, the samples were lyophilized, 
neutralized with buffer Tris-HCI, pH 5.0, and assayed as described 
above. Charring was carried out at 250°C for 2 h. In all cases the ap- 
propriate reagent controls were also included in the inhibition assay. 
Protein ~n~bations: 2 U of HHIF were incubated for 2 h at 37°C 
with 6 fig of phosphoiipase C or 10 Fg of BSA in 1 M Tris-HCI, pH 
7.4. The incubations were stopped by heating the samples at 80°C for 
10 min and centrifugation at 16000 x g for 5 min. The supernatants 
were then assayed for inhibition of Na+,K+-ATPase. Other inhibitors 
and related compounds: cholesterol, ouabain, digoxin, dopamine, 
OH tyrosine, digitoxin, phosphatidylcholinedioleyl, 
phosphatilaminedioleyl, lysophosphatidyiethanoienicleyi, OH- 
progesterone, androsterone, epiandrosterone, testosterone, chlor- 
manidone, arachidonic, linoleic, glycoquenodeoxycholic, 
glycocholic, quenodeoxycholic, OH-phenylacetic, OH- 
phenylpyruvic, OH-benzoic and OH-phenyllactic acids. 100-200 pg 
of these compounds were run in the final chromatographic system us- 
ed in the purification (see above) and their retention times and spectra 
recorded. 
3. RESULTS 
A crude extract was prepared from 1 kg of bovine 
hypothalamus, hypophysis or cerebral cortex as 
described in section 2. The extract equivalent o 250 g 
of tissue was chromatographed in a Sephadex LH-20 
column. The active fractions, eluting just before the 
salt peak, were concentrated by successive smaller 
LH-20 columna. At this stage of purification all 3 
tissues showed activity in all the assays, including 
digoxin immunoreactivity (fig.3). The specific in- 
hibitory activity at this purification step was of 1.5 U/g 
of tissue for hypothalamus and 3.4 U/g of tissue for 
hypophysis. The material was further purified in a 
semipreparative c18 ,uBondapak column as described in 
section 2. The area selected in the hypothalamic and 
h~ophys~y profiles from this column was active in all 
the assays, but did not show digoxin immunoreactivity. 
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Fig. 1. Elution profiles of the final purification by HPLC on an FFA 
column of 1Orm of particle size. The mobile phase was a step 
gradient of 20-409’0 during 60 min, 40-60% during 120 min and 
60-80% during 60 min of acetonitrile/water in 0.1% TFA at a flow 
rate of 0.5 mllmin. The sample injected corresponds to an initial 
weight of tissue of hypothalamus 350 g (A),. hypophysis 42 g (B), 
brain cortex 350 g (C). The arrow indicates the time of sample 
injection. Two-minute fractions, except for the peak area which was 
manually done, were collected and monitored for Na’,K+-ATPase 
inhibitory activity. Along the profiles, inhibitory activity was 
detected only in the peak that eluted at 108 min in the 
chromatograms A and B (see fig.2). The chromatogram Ccan be 
superimposed on the baseline obtained from injecting the same 
volume of distilled water (not shown). 
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Other areas, active only in one assay, were discarded. 
The profile of brain cortex showed inhibitory activity 
only in the void volume. From this stage on, the area 
in the brain cortex profile corresponding to the selected 
inhibitory area from the other two tissues, was submit- 
ted to the same purification steps as the active area in 
hypothalamus and hypophysis, and used as control. 
The next pu~~~ation steps, in analytical conditions, in- 
eluded a Crs Novapak and two FFA runs as described 
in section 2. In each column the sample injected ranged 
from 100 to 120 arbitrary units. In the case of brain 
cortex, where no activity was detected, the amount in- 
jetted corresponded to the equivalent fraction of 
hypoth~~us injected in each step. Fig.1 represents 
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Fig.2. inhibitory activity and spectral analysis of the peak fractions from the FFA column. The peak profiles were those of fig.fA,B. (Left) 
Localization of the inhibitory activity (0) in the peaks corresponding to hypothalamus (upper panel) and hypophysis (lower panel). (Right) 
Automatic overlay spectra obtained from right slope (A,B), peak maxima (C) and left slope (D,E) from 210-310 nm in the peaks corresponding 
to hypothalamus (upper panel) and hypophysis (lower panel). 
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the elution profile of the last FFA column in the 3 
tissues. The active material eluted as a single peak with 
a similar retention time in hypoth~~us and 
hypophysis. In the corresponding profile of cortex no 
peak or inhibitory activity was detected and it can be 
superimposed on the baseline obtained from injecting 
distilled water. Fig.2 shows the localization of in- 
hibitory activity in the peaks corresponding to 
hypoth~amus (upper left panel) and h~ophysis (lower 
left panel). The inhibitory activity determined in the 
standard coupled assay superimposes the absorbance in 
both peaks. The total inhibitory activity of the peaks is 
of 50 U for hypothalamus corresponding to 350 g of 
original tissue and of 105 U for hypophysis correspon- 
ding to 42 g of original tissue. The spectral analysis, in 
A 
2 
x 
P 0 
both peaks, showed a single component hroughout the 
peak (fig.2, right panels). With an autogain, all the 
spectra along each peak were superimposed (not 
shown) with a maximum of absorbance at 274 nm. 
The apparent molecular mass from ultrafiltration 
studies is < 1000 (Amicon Diaflo YM2, Amicon Co., 
Danvers). 500 U of HHIF were not measurable by a 
microbalance (Cahn 4700, Cerritos, CA: reproducible 
lower limit, 10 pg; readable lower limit, 1 Erg) because 
of too small amounts. Assuming a molecular mass of 
750, we can roughly estimate that the dose necessary to 
inhibit 50% the standard assay (1 U) is in the range of 
10e9 M. Charring at 250°C for 2 h destroyed the activi- 
ty and alkaline hydrolysis for 2 h destroyed 85% of the 
activity measured in the coupled assay. On the other 
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Fig.3. Inhibitory effect of purified hypothalamic (0) and hypophysary (0) factor on Na+,K+-ATPase activity (A), on binding of [‘Hlouabain 
to Na+,K+-ATPase (C) and cross-reactivity with antidigoxin antibody (E). Dose-response curves of these activities were determined in comparison 
with ouabain (A) (B,D,F) and digoxin (A) (E,F) under the same assay conditions. Each point is the mean of duplicate determinations in two 
separate xperiments and in A to D using two different preparations of Na+,K+-ATPase. Results are expressed as the percentage of maximal 
Na+,K+-ATPase activity, maximal binding of 13H]ouabain to Na+,K+-ATPase, and maximal binding of [‘251]digoxin to anti-digoxin antibody. 
The cross-reactivity of partially purified hypothalamic factor (0) is also represented in E (see text). 
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hand, the activity was not affected by acid hydrolysis 
or by phospholipase C digestion (see section 2). The in- 
cubation with BSA did not affect the inhibitory activity 
suggesting that this factor is not lipidic [lo]. The lipidic 
extraction residue (chloroform and petroleum ether 
residues) [4,5] obtained from 1 kg of hypothalamic 
tissue was processed through the purification protocol 
in the same fashion as the tissues, obtaining no in- 
hibitory activity or characteristic peak in the final 
purification step, suggesting that we are not dealing 
with a lipidic substance not totally extracted by organic 
solvents. The inhibition of ATPase by unsaturated fat- 
ty acids and lysophosphatidylcholines [8,1 l] is produc- 
ed by much higher concentrations than the one 
calculated for the HHIF. The purified factors obtained 
from hypothalamus and hypophysis were compared 
with ouabain for inhibition of Na+,K+-ATPase, 
[3H]ouabain binding to the enzyme and [‘2SI]digoxin 
binding to anti-digoxin antibody (fig.3). For these 
studies the same definition of unit was used, that is, the 
amount necessary to inhibit 50% of Na+,K+-ATPase in 
the coupled assay (25 mM K+ and 2 h incubation), but 
the concentration of Kf used in the coupled assay was 
5 mM. The biological activity of the factor purified 
from both tissues is superimposed in the dose-response 
curves. The curves of [3H]ouabain displacement ob- 
tained with HHIF or ouabain were parallel (fig.3C,D). 
However, the slopes of the dose-response curves of AT- 
Pase inhibition were different for HHIF and ouabain 
(fig.3A,B). The purified HHIF did not cross-react with 
the anti-digoxin antibody at the doses tested, while oua- 
bain cross-reacted weakly (fig.3E,F). Partially purified 
hypothalamic factor, obtained in the lipophilic 
chromatography did show cross-reactivity with this an- 
tibody. The chromatography under the same condi- 
tions as in fig. 1, of several compounds known to inhibit 
Na+,K+-ATPase or related to them (see section 2) 
shows that none had a retention time nor spectra 
similar to the HHIF. 
4. DISCUSSION 
An endogenous Na+,K+-ATPase inhibitor is con- 
sidered to be a key factor in the pathogenesis of essen- 
tial hypertension and the midbrain has been postulated 
as the origin of such a factor [l]. Several groups have 
found inhibitory activity in crude extracts of brain, 
plasma and urine [2] but there is disagreement about 
the chemical structure and mechanism of action due, 
most probably, to the mixture of compounds in the 
preparations. We have previously reported the presence 
of such an inhibitor in extracts of bovine hypothalamic 
[3] and hypophysary [4] tissues. The present study 
reports the complete purification of the inhibitor in 
parallel from both tissues to apparent homogeneity, 
and the evidence that we are dealing with the same com- 
pound. Its absence in brain cortex and the higher con- 
440 
centrations in hypophysis suggest some form of storage 
in the latter. This compound has a characteristic UV 
spectrum and is a potent inhibitor of the Na+-pump at 
physiological concentrations of K+. These two 
characteristics make our compound completely dif- 
ferent from the, up until now, only other tissue in- 
hibitor already purified, using bovine adrenal gland as 
a source [12,13]. The complete purification of this fac- 
tor is hazardous because the assay systems employed 
are prone to interference by a number of artifacts [14]. 
We have overcome these difficulties by the use of a 
multiassay strategy for the detection of inhibitory ac- 
tivity. In this way we have been able to eliminate false 
positive areas since each assay is prone to interference 
by differing substances. The decrease of cross- 
reactivity with anti-digoxin antibodies during the 
purification procedure indicates the risk of using such 
a parameter as a marker in the purification of 
analogous factors. This non-peptidic, non-lipidic in- 
hibitor has a molecular mass of less than 1000 and it is 
destroyed by alkaline hydrolysis or ashing. Its 
chromatographic characteristics and spectral features 
are different from any of the substances tested. The 
obtention, by the method described, of sufficient 
amounts of pure material of this unique compound will 
permit the study of the chemical nature and the elucida- 
tion of its mechanism of action and, therefore, of the 
role that it may play in the physiopathology of 
hypertension. 
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